RPG Life Sciences Ltd. has named Deepak Shukla as CEO – API Business, marking a significant leadership addition as the company sharpens its focus on scaling its active pharmaceutical ingredients (API) operations. With more than 20 years of experience in the pharmaceutical and specialty chemicals industries, Shukla brings deep expertise in operational excellence, business expansion, and global partnerships to his new role.
Over the course of his career, Shukla has held senior leadership positions across some of the world’s most respected pharmaceutical and chemical organizations. Most recently, he served as Chief Operating Officer, Pharma Ventures (Specialty Chemicals) at UPL, where he played a pivotal role in expanding the business footprint and driving innovation. Prior to UPL, he contributed to global growth and operational leadership at Teva Pharmaceuticals, AkzoNobel, Ranbaxy Laboratories, Dr. Reddy’s Laboratories, and Atul Limited.
This diverse background, spanning both pharmaceuticals and specialty chemicals, has equipped Shukla with the ability to navigate complex global markets, scale high-performance teams, and implement strategies that deliver both growth and sustainability. His international experience positions him strongly to steer RPG Life Sciences’ API business into its next phase of growth and innovation.
RPG Life Sciences, a part of the RPG Group, is a fully integrated pharmaceutical company with a strong presence in domestic and international markets. Its API business plays a critical role in supplying key ingredients for formulations across therapeutic areas. With the sector undergoing rapid transformation—driven by rising demand for cost-effective generics, supply chain diversification, and increasing regulatory scrutiny—the company views leadership in this vertical as central to its long-term growth agenda.
The appointment of Shukla underscores RPG Life Sciences’ commitment to strengthening its API business through strategic leadership, global collaborations, and operational efficiency. By leveraging his proven track record, the company aims to enhance its competitiveness in international markets, expand its API portfolio, and reinforce its position as a reliable partner for pharmaceutical companies worldwide.
With Shukla at the helm, RPG Life Sciences’ API division is expected to focus on innovation-led growth, customer-centricity, and expanding its global footprint, aligning with the company’s larger vision of sustainable and scalable healthcare solutions.
